- Home
- PLX vs CRBU Comparison
PLX vs CRBU Comparison
Compare PLX & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLX | CRBU |
|---|---|---|
| Founded | 1993 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.4M | 166.6M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PLX | CRBU |
|---|---|---|
| Price | $2.37 | $1.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $12.00 | $10.75 |
| AVG Volume (30 Days) | 641.2K | ★ 2.5M |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $52,744,000.00 | N/A |
| Revenue This Year | $36.81 | $1.63 |
| Revenue Next Year | N/A | $10.93 |
| P/E Ratio | $10.82 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.36 | $1.38 |
| 52 Week High | $3.19 | $3.53 |
Technical Indicators
Market Signals| Indicator | PLX | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 64.79 | 54.50 |
| Support Level | $2.06 | $1.86 |
| Resistance Level | $2.42 | $2.02 |
| Average True Range (ATR) | 0.10 | 0.13 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 83.38 | 60.91 |
Price Performance
Historical ComparisonAbout PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.